HPV-Hr detection by home self sampling in women not compliant with pap test for cervical cancer screening. Results of a pilot programme in Bouches-du-Rhône;L'auto-prélèvement vaginal à domicile pour recherche de papilloma virus à haut risque. Campagne expérimentale du département des Bouches-du-Rhône

Bulletin du Cancer

Volumn 98, Issue 7, 2011, Pages 723-731

  Piana, Lucien ^a   Leandri, François Xavier ^a   Le Retraite, Laurence ^a   Heid, Patrice ^a   Tamalet, Catherine ^b   Sancho Garnier, Hélène ^c  

^a Assoc Pour la Rech et le Depistage des Cancers du Sein   (France)

^b TIMONE HOSPITAL   (France)

^c CENTRE VAL D AURELLE   (France)

Author keywords

Cervical screening; Follow up; HPV Hr self sampling; Participation rate

Indexed keywords

ADULT; ARTICLE; CANCER PATIENT; CANCER SCREENING; COMPARATIVE STUDY; CONTROLLED STUDY; FEMALE; FOLLOW UP; HUMAN; MAJOR CLINICAL STUDY; MORTALITY; PAPANICOLAOU TEST; PAPILLOMAVIRUS INFECTION; PATIENT PARTICIPATION; RANDOMIZED CONTROLLED TRIAL; SOCIAL STATUS; UTERINE CERVIX CANCER; UTERINE CERVIX CARCINOMA IN SITU;

EID: 79960567780     PISSN: 00074551     EISSN: 17696917     Source Type: Journal    
DOI: 10.1684/bdc.2011.1388     Document Type: Article

References (41)

1. http://www.invs.sante.fr (consulté en mars 2010).
2. Van Ballegooijen M, Van Den Akker-van Marle E, Patnick J, et al. Overview of important cervical cancer screening process values in European Union (EU) countries, and tentative predictions of the corresponding effectiveness and cost-effectiveness. Eur J Cancer 2000 ; 36 : 2177-88.
3. Peto J, Gilham C, Fletcher O, Matthews FE. The cervical cancer epidemic that screening has prevented in the UK. Lancet 2004 ; 364 : 249-56. (Pubitemid 38942814)
4. Sasieni PD, Cuzick J, Lynch-Farmery E. Estimating the efficacy of screening by auditing smear histories of women with and without cervical cancer. Br J Cancer 1996 ; 73 : 1001-5. (Pubitemid 26116757)
5. Kinney W, Sung HY, Kearney KA, Miller M, Sawaya G, Hiatt RA. Missed opportunities for cervical cancer screening of HMO members developing invasive cervical cancer (ICC). Gynecol Oncol 1998 ; 71 : 428-30. (Pubitemid 29022332)
6. Jacqueme B, Coudert C, Mabriez JC, Bonnier P, Piana L. Antécédents de dépistage cytologique chez les patientes traitées pour cancer infiltrant du col de l'utérus. Bull Cancer 2002 ; 89 : 234-40. (Pubitemid 34242291)
7. Schaffer P, Sancho-Garnier H, Fender M, et al. Cervical cancer screening in France. Eur J Cancer 2000 ; 36 : 2215-20.
8. Piana L, Leandri FX, Jacqueme B, et al. Le dépistage organisé des cancers du col utérin pour les femmes en situation médicosociale défavorisée. Bull Cancer 2007 ; 94 : 461-7.
9. Wacogne A. La prévention en matière de santé chez les personnes en situation de précarité : attitudes face aux campagnes et aux messages préventifs. Mémoire d'administration économique et sociale. Arcades, 2002.
10. Peters RK, Bear MB, Thomas D. Barriers to screening for cancer of the cervix. Prev Med 1989 ; 18 : 133-46. (Pubitemid 19128817)
11. Harlan LC, Bernstein AB, Kessler LG. Cervical cancer screening: who is not screened and why? Am J Public Health 1991 ; 81 : 885-90.
12. Paskett ED, Rushing J, D'Agostino Jr. R, Tatum C, Velez R. Cancer screening behaviors of low-income women: the impact of race. Women's Health 1997 ; 3 : 203-26.
13. Walboomers JM, Jacobs MV, Manos MM, et al. Human papillomavirus is necessary cause of invasive cervical cancer worldwide. J Pathol 1999 ; 189 : 12-9. (Pubitemid 29406813)
14. Cuzick J. Human papillomavirus testing for primary cervical cancer screening. JAMA 2000 ; 283 : 108-9. (Pubitemid 30038393)
15. Sherman ME, Lorincz AT, Scott DR, et al. Baseline cytology, human papillomavirus testing, and risk for cervical neoplasia: a 10-year cohort analysis. J Natl Cancer Inst 2003 ; 95 : 46-52. (Pubitemid 36124295)
16. Sanner K, Wikström I, Strand A, Lindell M, Wilander E. Selfsampling of the vaginal fluid at home combined with high-risk HPV testing. Br J Cancer 2009 ; 101 : 871-4.
17. Dalstein V, Riethmuller D, Prétet JL, et al. Persistence and load of high-risk HPV are predictors for development of high-grade cervical lesions: a longitudinal French cohort study. Int J Cancer 2003 ; 106 : 396-403. (Pubitemid 36870403)
18. Morris BJ, Rose BR. Cervical screening in the 21st century: the case for human papillomavirus testing of self-collected specimens. Clin Chem Lab Med 2007 ; 45 : 577-91.
19. Franco EL, Villa LL, Sobrinho JP, et al. Epidemiology of acquisition and clearance of cervical human papillomavirus infection in women from a high-risk area for cervical cancer. J Infect Dis 1999 ; 180 : 1415-23. (Pubitemid 29506440)
20. Cox T, Cuzick J. HPV DNA testing in cervical cancer screening: from evidence to policies. Gynecol Oncol 2006 ; 103 : 8-11. (Pubitemid 44374720)
21. Baay MF, Tjalma WA, Lambrechts HA, et al. Combined Pap and HPV testing in primary screening for cervical abnormalities: should HPV detection be delayed until age 35? Eur J Cancer 2005 ; 41 : 2704-8. (Pubitemid 41607562)
22. Kjaer S, Hogdall E, Frederiksen K, et al. The absolute risk of cervical abnormalities in high-risk human papillomavirus-positive, cytologically normal women over a 10-year period. Cancer Res 2006 ; 66 : 10630-6. (Pubitemid 44799787)
23. Brink A, Meijer C, Wiegerinck M, et al. High concordance of results of testing for human Papillomavirus in cervicovaginal samples collected by two methods, with comparison of a novel self-sampling device to a conventional endocervical brush. J Clin Microbiol 2006 ; 44 : 2518-23. (Pubitemid 44092421)
24. Wright TC, Denny L, Kuhn L, et al. HPV DNA testing of self-collected vaginal samples compared with cytologic screening to detect cervical cancer. JAMA 2000 ; 283 : 81-6. (Pubitemid 30038387)
25. Finan RR, Irani-Hakime N, Tamim H, et al. Molecular diagnosis of human papillomavirus: comparison between cervical and vaginal sampling. Infect Dis Obstet Gynecol 2001 ; 9 : 119-22. (Pubitemid 32666610)
26. Harper DM, Hildesheim A, Cobb JL, Greenberg M, Vaught J, Lorincz AT. Collection devices for human papillomavirus. J Fam Pract 1999 ; 48 : 531-5.
27. Harper DM, Noll WW, Belloni DR, et al. Randomized clinical trial of PCR-determined human papillomavirus detection methods: self-sampling versus clinician-directed - biologic concordance and women's preferences. Am J Obstet Gynecol 2002 ; 186 : 365-73. (Pubitemid 34234143)
28. Sellors JW, Lorincz AT, Mahony JB, et al. Comparison of self-collected vaginal, vulvar and urine samples with physician-collected cervical samples for human papillomavirus testing to detect highgrade squamous intraepithelial lesions. CMAJ 2000 ; 163 : 513-8.
29. Dzuba IG, Diaz EY, Allen B, et al. The acceptability of self-collected samples for HPV testing vs. the Pap test as alternatives in cervical cancer screening. J Women's Health Gender-Based Med 2002 ; 11 : 265-74.
30. Waller J, McCaffery K, Forrest S, et al. Acceptability of unsupervised HPV self-sampling using written instructions. J Med Screen 2006 ; 13 : 208-13. (Pubitemid 46057729)
31. Stenvall H, Wikstrom I, Backlund I, Wilander E. Accuracy of HPV testing of vaginal smear obtained with a novel self-sampling device. Acta Obstet Gynecol Scand 2007 ; 86 : 16-21. (Pubitemid 46009520)
32. Ronco G, Giorgi-Rossi P, Carozzi F, et al. Efficacy of human papillomavirus testing for the detection of invasive cervical cancers and cervical intraepithelial neoplasia: a randomised controlled trial. Lancet Oncol 2010 ; 11 : 249-57.
33. Tamalet C, Richet H, Carcopino X, et al. Testing for human papillomavirus and measurement of viral load of HPV 16 and 18 in self-collected vaginal swabs of women who do not undergo cervical cytological screening in Southern France. J Med Virol 2010 ; 82 : 1431-7.
34. Woodman CB, Collins S, Winter H, et al. Natural history of cervical human papillomavirus infection in young women: a longitudinal cohort study. Lancet 2001 ; 357 : 1831-6. (Pubitemid 32539115)
35. Winer RL, Kiviat NB, Hughes JP, et al. Development and duration of human papillomavirus lesions, after initial infection. J Infect Dis 2005 ; 191 : 731-8. (Pubitemid 40271061)
36. Schiffman M, Herrero R, Desalle R, et al. The carcinogenicity of human papillomavirus types reflects viral evolution. Virology 2005 ; 337 : 76-84. (Pubitemid 40725441)
37. Melkert PW, Hopman E, van den Brule AJ, et al. Prevalence of HPV in cytomorphologically normal cervical smears, as determined by the polymerase chain reaction, is age-dependent. Int J Cancer 1993 ; 53 : 919-23. (Pubitemid 23119536)
38. Burk RD, Kelly P, Feldman J, et al. Declining prevalence of cervicovaginal human papillomavirus infection with age is independent of other risk factors. Sex Transm Dis 1996 ; 23 : 333-41. (Pubitemid 26250669)
39. Cuzick J, Beverley E, Ho L, et al. HPV testing in primary screening of older women. Br J Cancer 1999 ; 81 : 554-8. (Pubitemid 29458814)
40. Baay MF, Smits E, Tjalma WA, et al. Can cervical cancer screening be stopped at 50? The prevalence of HPV in elderly women. Int J Cancer 2004 ; 108 : 258-61. (Pubitemid 37541780)
41. Rousseau A, Bohet P, Merliere J, Treppoz H, Heules-Bernin B. Évaluation du dépistage organisé et dépistage des données de l'assurance maladie. BEH 2002 ; 19 : 81-3.